Nanosphere, which develops, manufactures and markets an advanced molecular diagnostics platform, filed terms with the SEC Wednesday for its upcoming IPO. The company plans to offer 7 million shares at a price range of $14 to $16 per share. Credit Suisse is the lead manager on the deal.
